SCHEMBL962215

SCHEMBL962215

CC(C)(C)c1cc(CO)cc(C(C)(C)C)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.52
GABRB2 P47870 1/20 0.52
ACHE P22303 1/20 0.42
RXRA P19793 3/20 0.41
RXRB P28702 3/20 0.41
RXRG P48443 3/20 0.41
EPHX2 P34913 1/20 0.39
HMGCR P04035 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTR1D P28221 2/20 0.38
HTR1B P28222 1/20 0.38
POLB P06746 1/20 0.37
IKBKB O14920 1/20 0.37
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
LMNA P02545 1/20 0.35
TYR P14679 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17393750 0.95 GABRA1 (0.46) GABRA1GABRB2ACHERXRARXRB
SCHEMBL2422576 0.91 GABRA1 (0.44) GABRA1GABRB2ACHERXRARXRB
SCHEMBL2424035 0.91 GABRA1 (0.44) GABRA1GABRB2ACHERXRARXRB
SCHEMBL12871778 0.89 RXRA (0.45) GABRA1GABRB2RXRARXRBRXRG
SCHEMBL14228428 0.86 HSPA5 (0.40) GABRA1GABRB2ACHERXRARXRB
SCHEMBL19051205 0.86 TACR1 (0.43) GABRA1GABRB2ACHERXRARXRB
SCHEMBL12115600 0.86 GABRA1 (0.62) GABRA1GABRB2ACHERXRARXRB
SCHEMBL12187819 0.84 GABRA1 (0.38) GABRA1GABRB2ACHERXRARXRB
SCHEMBL19294284 0.84 GABRA1 (0.38) GABRA1GABRB2ACHERXRARXRB
SCHEMBL12871594 0.84 CYP4F2 (0.44) GABRA1GABRB2ACHERXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119330805-A Preparation method of 3, 5-di-tert-butyl benzyl alcohol 宁夏忠同生物科技有限公司 2025-01-21 CN claimed
EP-2961818-A1 TRICRESYL PHOSPHATE-FREE OIL, LUBRICANT OR TURBINE OIL Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2016-01-06 EP claimed
WO-2014131571-A1 TRICRESYL PHOSPHATE-FREE OIL, LUBRICANT OR TURBINE OIL Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2014-09-04 WO claimed
CN-101331138-A One-pot synthesis of tetrazole derivatives of sirolimus ABBOTT LAB (US) 2008-12-24 CN claimed
EP-1146905-A1 COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN Algos Pharmaceutical Corporation (US) 2001-10-24 EP claimed
WO-2000029022-A1 COX-2 INHIBITORS IN COMBINATION WITH CENTRALLY ACTING ANALGESICS ALGOS PHARMACEUTICAL CORPORATION (US) 2000-05-25 WO claimed
WO-2000029023-A1 COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN ALGOS PHARMACEUTICAL CORPORATION (US) 2000-05-25 WO claimed
WO-1998050075-A1 COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN ALGOS PHARMACEUTICAL CORPORATION (US) 1998-11-12 WO claimed
US-5175201-A VINYL-TERMINATED CARBAMYLMETHYLATED MELAMINES, VINYL-TERMINATED POLYURETHANE/POLYAMIDE POLYMERS AND COATING/ADHESIVE COMPOSITIONS CONTAINING SAME AMERICAN CYANAMID COMPANY (US) 1992-12-29 US claimed
JP-58145751-A None JP disclosed
JP-56125307-A None JP disclosed
US-20260103473-A1 CITRATE SALT OF CYCLIN-DEPENDENT KINASE (CDK4/6) INHIBITOR, CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF AVANC PHARMACEUTICAL CO LTD (CN) 2026-04-16 US disclosed
EP-4652167-A1 GLP-1R AGONISTS AND USES THEREOF Fochon Biosciences, Ltd. (CN) 2025-11-26 EP disclosed
US-12312349-B2 Apoptosis-inducing agents FOCHON PHARMACEUTICALS, LTD. (CN) 2025-05-27 US disclosed
US-4397783-A HYDRODEHALOGENATION WITH AN ORGANOTIN HYDRIDE PFIZER INC. (US) 1983-08-09 US disclosed
JP-S56125307-A FIRST LIQUID FOR PERMANENT WAVE HOOU KK 1981-10-01 JP disclosed
US-4187338-A PLASTICIZED POLYVINYL CHLORIDE, SYNTHETIC RUBBER LONSEAL CORPORATION (JP) 1980-02-05 US disclosed
US-4167415-A Photocurable composition comprising copolymer of maleic acid monoester and α-olefin compound KANSAI PAINT CO., LTD. (JP) 1979-09-11 US disclosed
US-4092172-A Photocurable composition comprising a copolymer of a maleic acid monoester with an α-olefine KANSAI PAINT CO., LTD. (JA) 1978-05-30 US disclosed
US-4020125-A HYDROGENATED POLYBUTADIENE-DIOL MODIFIED BY ISOCYANATES AND HYDROXYALKYL ACRYLATES NIPPON SODA COMPANY LIMITED (JA) 1977-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12312349-B2 Apoptosis-inducing agents BCL2, BAX, BAD GABRA1 3862/4885GABRB2 2134/4885ACHE 4351/4885
US-20260103473-A1 CITRATE SALT OF CYCLIN-DEPENDENT KINASE (CDK4/6) INHIBITOR, CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF CDK4, CDK1, CDK6 GABRA1 3578/4885GABRB2 3630/4885ACHE 4709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.